Genetics Institute, Inc.

Ludwig Institute for Cancer Research Limited

Steven C. Clark

Agnes B. Ciarletta

Yu-Chung Yang

Robert E. Donahue

Susan T. Ricciardi

Agnes B Ciarletta

Steven C Clark

Robert E Donahue

Susan T Ricciardi

This invention provides a novel human erythropoietic growth factor and processes for producing it by recombinant DNA genetic engineering techniques.

DNA encoding the human cytokine, interleukin-9

A method of treating leukopenia, by administering an IL-3 polypeptide, is disclosed.

Therapeutic uses of IL-3

The invention involves DNA molecules which encode a human protein of 144 amino acids, referred to as interleukin-9, or IL-9. The protein is an erythropoietic growth factor. Also disclosed are processes for producing the IL-9 protein via genetic engineering techniques.

Provided by the present invention is a novel cytokine, IL-9, an approximately 144 amino acid protein, characterized by an apparent molecular weight of between 20 to 30 kD and having biological activity in an MO7E cell assay. The cytokine can be used, inter alia, as a mitogen, as an antigen, and to regulate hematopoiesis.

Human cytokine IL-9

An improved method for inducing leukocytosis in a primate is disclosed. The method includes co-administering IL-3 in conjunction with GM-CSF, such that the leukocyte count in the primate is synergistically raised.

Method of inducing leukocytosis with a combination of IL-3 and GM-CSF

A novel family of primate IL-3 polypeptides is provided via recombinant techniques.

Primate hematopoietic growth factors IL-3 and pharmaceutical compositions

A novel family of primate IL-3-like polypeptides is provided via recombinant techniques.

Growing community of inventors

Haverhill, MA, United States of America

Agnes B Ciarletta